Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more) Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

Recent & Breaking News (NDAQ:LEXX)

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Accesswire December 8, 2021

Lexaria's DehydraTECH(TM)-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

TheNewsWire December 8, 2021

Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Newsfile December 6, 2021

Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes

TheNewsWire November 10, 2021

Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4

TheNewsWire November 3, 2021

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol

Accesswire November 1, 2021

Lexaria THC Test Results Come in as MORE Act Gains Momentum in Congress

Newsfile October 20, 2021

Lexaria Bioscience’s technology proven to deliver oral THC more effectively

Stockhouse Editorial October 14, 2021

Lexaria's Technology Proven to Deliver Oral THC More Effectively

TheNewsWire October 13, 2021

DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete

Newsfile October 5, 2021

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

TheNewsWire October 5, 2021

BTV Highlights Promising Investment Opportunities

Newsfile September 23, 2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

GlobeNewswire September 16, 2021

Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System

GlobeNewswire September 15, 2021

Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

TheNewsWire September 9, 2021

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

Accesswire September 8, 2021

BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs

Newsfile September 7, 2021

Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period

TheNewsWire September 7, 2021

Winning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology

Newsfile August 17, 2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

GlobeNewswire August 6, 2021